<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171325</url>
  </required_header>
  <id_info>
    <org_study_id>CTONG1402</org_study_id>
    <nct_id>NCT02171325</nct_id>
  </id_info>
  <brief_title>Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment</brief_title>
  <official_title>A Phase Ⅱ Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Association of Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the appropriate dose of irinotecan by dose&#xD;
      escalation(dose climbing) test. The study would provide rationale for regimen decision in a&#xD;
      future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be&#xD;
      selected as therapeutic drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in&#xD;
      patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limiting Toxicity (DLT )in the irinotecan</measure>
    <time_frame>up to 18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose(MTD)in the irinotecan</measure>
    <time_frame>up to 18weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2</description>
    <arm_group_label>irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 65 years, male and female&#xD;
&#xD;
          2. Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC&#xD;
             )（except metastases only as pleural effusion）&#xD;
&#xD;
          3. No prior chemotherapy&#xD;
&#xD;
          4. Metastatic lesion had been treated more than 14 days by palliative radiation therapy&#xD;
             or surgery&#xD;
&#xD;
          5. With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy&#xD;
             ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need&#xD;
             short diameter need more then 15mm, and the lesions can be accurately evaluated&#xD;
             repeatedly measurable)&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1&#xD;
&#xD;
          7. Expected survival ≥ 3months&#xD;
&#xD;
          8. Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of&#xD;
&#xD;
               -  absolute neutrophil coun(ANC) ≥ 2.0 × 109 / L&#xD;
&#xD;
               -  blood platelet(PLT) ≥ 100 × 109 / L&#xD;
&#xD;
               -  Hb≥ 90g / L&#xD;
&#xD;
               -  conjugative bilirubin(CB)≤ upper limit of normal(ULN) × 1.5&#xD;
&#xD;
               -  Aspartate transaminase(AST )(glutamic oxalacetic transaminase,GOT): ≤ upper limit&#xD;
                  of normal(ULN )× 2.5&#xD;
&#xD;
               -  Alanine aminotransferase(ALT)(Glutamate Pyruvate Transaminase,GPT): ≤ ULN × 2.5&#xD;
&#xD;
               -  Serum creatinine: ≤ ULN or calculated creatinine clearance≥ 60 ml / min&#xD;
&#xD;
               -  (PT INR) ≤ ULN × 1.5&#xD;
&#xD;
               -  ECG: no abnormalities in need of treatment&#xD;
&#xD;
          9. No pregnancy or no pregnancy demand at the end of the study within six months&#xD;
&#xD;
         10. Must provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient have platinum compounds allergy history&#xD;
&#xD;
          2. Patient with active ulcer disease or chronic enteritis patients&#xD;
&#xD;
          3. Primary lesion(s) has (have) been treated by Surgery or radiation&#xD;
&#xD;
          4. Patient had received Immune drugs treatment for anti-lung cancer indications or&#xD;
             anti-cancer Chinese traditional medicine treatment within two weeks&#xD;
&#xD;
          5. Patients with interstitial pneumonia or pulmonary fibrosis&#xD;
&#xD;
          6. Brain metastasis requiring treatment&#xD;
&#xD;
          7. Patient with bronchus or bronchial stenosis or blockage and superior vena cava&#xD;
             syndrome caused by serious invasion&#xD;
&#xD;
          8. Patients with severe infections, severe abnormal secretion of (Anti Diuretic&#xD;
             Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring&#xD;
             treatment vena cava syndrome&#xD;
&#xD;
          9. Severe cardiovascular disease: hypertension that medical treatment can not be&#xD;
             controlled , unstable angina, myocardial infarction within the last June a history of&#xD;
             congestive heart failure&gt; 3 (NYHA) and severe arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ying cheng, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jilin Provincial Tumor Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ying cheng, doctor</last_name>
    <phone>86-43185871902</phone>
    <email>jl.cheng@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>qian liu, bachelor</last_name>
    <phone>86-43185873196</phone>
    <email>xjy0202@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jilin cancer hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ying cheng, doctor</last_name>
      <phone>86-43185871902</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irinotecan</keyword>
  <keyword>Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

